according to individual tyrosine kinase inhibitor (TKI) at time of surgery calculated from the start of TKI therapy.
Supplemental Table 1. Univariate analysis of treatment and tumor variables on progression- free survival and overall survival for all patients with gastrointestinal stromal tumor treated with TKI at time of metastasectomy (n = 400).
Variables
Progression-free survival Overall survival Median (mos) P-value Median (mos) P-value Duration of preoperative TKI
≤24 mo
>24 mo
12.6
8.8 0.001 91.0
66.9 0.227
Radiographic response Responsive
Stable
Unifocal progression Multifocal progression
31.2 19 9.6 5.3
<0.001
Not reached 109.9
54.1 25.9
<0.001 Location of disease
Liver only Peritoneum only Both
Other
19.8 11 7.4 12.6
<0.001
Not reached 59.4 89.6 66.9
0.077 Metastatic mitotic index
<5/50 HPF
≥5/50 HPF
31.6
6.9 <0.001 Not reached
49.7 <0.001 Primary mutation of metastasis
Exon 11 Exon 9 Other
12.1 10.4
12 0.718
57.7 91.0
115.1 0.083
Extent of resection R0
R1 R2
17.3 12.6
5.7 <0.001
109.9 91.0
26.8 <0.001 Number of metastases
≤5
>5 12.2
7.3 <0.001 86.5
71.6 0.125
Recurrence pattern Local
Distant
Local and distant
8.0 12.2
8.6
0.012 51.5
74.9 80.9
0.333 Abbreviations: TKI, tyrosine kinase inhibitor; HPF, high-powered field.
free survival and overall survival for patients with gastrointestinal stromal tumor treated with imatinib at time of metastasectomy (n = 234).
Variables
Progression-free survival Overall survival Median (mos) P-value Median (mos) P-value Duration of preoperative TKI
≤24 mo
>24 mo
25.4 11.5
0.003 109.9
59.4
0.003 Radiographic response
Responsive Stable
Unifocal progression Multifocal progression
36.3 30.4 10.8 6.3
<0.001 not reached 109.9
59.4 24.3
<0.001
Location of disease Liver only Peritoneum only Both
Other
28.6 14.8 10.9 12.2
0.01 Not reached 86.5 104.9
66.9
0.269
Metastatic mitotic index
<5/50 HPF
≥5/50 HPF
31.6 9.1
<0.001 Not reached 54.1
0.001 Primary mutation of metastasis
Exon 11 Exon 9 Other
19.1 10.4 15.3
0.89 57.7
91.0 115.1
0.302
Extent of resection R0
R1 R2
26.0 19.8 6.9
0.001 109.9
104.7 40.8
0.006 Number of metastases
≤5
>5
18.5 14
0.008 104.7
71.6
0.206 Recurrence pattern
Local Distant
Local and distant
12.0 20.5 15.6
0.124 86.5
109.9 Not reached
0.826
Supplemental Table 3. Univariate analysis of treatment and tumor variables on progression- free survival and overall survival for patients with gastrointestinal stromal tumor treated with sunitinib at time of metastasectomy (n = 93).
Variables
Progression-free survival Overall survival Median (mos) P-value Median (mos) P-value Duration of preoperative TKI
≤24 mo
>24 mo
7.6 6.0
0.211
34.4 48.2
0.438 Radiographic response
Responsive Stable
Unifocal progression Multifocal progression
12.6 7.9 8.5 5.3
0.093
Not reached 80.9 51.5 25.9
0.423
Location of disease Liver only Peritoneum only Both
Other
5.3 7.4 5.4 41
0.202
48.2 32.6 89.6 23.7
0.683
Metastatic mitotic index
<5/50 HPF
≥5/50 HPF
35.8 5.3
0.001
Not reached 32.8
0.055 Primary mutation of metastasis
Exon 11 Exon 9 Other
5.3 12.4 11.2
0.013
48.2 Not reached Not reached
0.516 Extent of resection
R0 R1 R2
12.2 6.9 5.4
0.196
34.4 89.6 23.9
0.019 Number of metastases
≤5
>5
8.5 5.3
0.045
51.5 23.9
0.177 Recurrence pattern
Local Distant
Local and distant
7.4 7.2 4.9
0.412
27.6 34.4 80.9
0.356
Abbreviations: TKI, tyrosine kinase inhibitor; HPF, high-powered field.
survival and overall survival for all patients with gastrointestinal stromal tumor treated with sunitinib at time of metastasectomy (n = 93).
Variables
Progression-free survival Overall survival Hazard Ratio
(CI) P-value Hazard Ratio
(CI) P-value Metastatic mitotic index
<5/50 HPF
≥5/50 HPF
Ref
10.74 (1.28 – 89.98)
- 0.029
- -
Primary mutation of metastasis Other
Exon 11 Exon 9
Ref
1.77 (0.64 – 4.86) 0.83 (0.28 – 2.48)
- 0.270 0.738
- -
Extent of resection R0
R1 R2
- -
Ref
0.45 (0.16 – 1.27) 1.52 (0.64 – 3.60)
0.132 0.341 Number of metastases
≤5
>5
Ref
2.03 (0.77 – 5.33)
- 0.153
- -
Abbreviations: CI, 95% confidence interval; TKI, tyrosine kinase inhibitor; Ref, reference; HPF, high-power field.
